Thromboembolism
Conditions
Brief summary
The purpose of this study is to evaluate the health care resource utilization and costs associated with treating patients diagnosed with cancer and venous thromboembolism with apixaban or low molecular weight heparin. This is a retrospective database analysis of health care claims data. All-cause costs as well as costs associated with recurrent VTE, major bleeding, and clinically relevant nonmajor bleeding will be assessed.
Interventions
None listed
Sponsors
Bristol-Myers Squibb
Pfizer
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Venous thromboembolism (VTE) diagnosis between January 1 2017 and October 31 2021 * Evidence of active cancer * At least 1 claim for apixaban or low molecular weight heparin (LMWH) * Age 18 years or older
Exclusion criteria
* diagnosis of atrial fibrillation/flutter * procedure for mechanical heart valve or inferior vena cava filter * VTE diagnosis in the baseline period * anticoagulant therapy in the baseline period * pregnancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mean All-Cause Hospitalization Costs PPPM for CRNM Bleeding Related VTE Events | From index date until health plan disenrollment, index therapy discontinuation, switch to another anticoagulant or end of study period (up to 72 months); data observed retrospectively over 24 months | CRNM bleeding was defined as an inpatient encounter with a secondary diagnosis code for bleeding (without a major bleeding code in the primary position) or an outpatient encounter with a diagnosis code in any position for CRNM GI bleeding or other non-critical types of bleeding. Any CRNM bleeding events that followed a major bleeding event were not included in the analysis of CRNM bleeding. Costs were converted to 2021 USD using the medical component of the consumer price index and was expressed as cost per participant per month. The date of the first apixaban or LMWH prescription on or within the 30 days following a VTE diagnosis was considered as the index date. |
| Mean All-Cause Healthcare Hospitalization Costs PPPM for VTE Events | From index date until health plan disenrollment, index therapy discontinuation, switch to another anticoagulant or end of study period (up to 72 months); data observed retrospectively over 24 months | The all-cause healthcare hospitalization cost for VTE event was defined as the cost associated with the inpatient hospitalization for the VTE event. Costs were converted to 2021 USD using the medical component of the consumer price index and was expressed as cost per participant per month. The date of the first apixaban or LMWH prescription on or within the 30 days following a VTE diagnosis was considered as the index date. |
| Mean All-Cause Healthcare Costs PPPM for Recurrent VTE Events | From index date until health plan disenrollment, index therapy discontinuation, switch to another anticoagulant or end of study period (up to 72 months); data observed retrospectively over 24 months | Recurrent VTE was identified based on inpatient claims with VTE as the primary diagnosis on any claim (international classification of diseases, tenth revision, clinical modification \[ICD-10-CM\] diagnosis codes). Recurrent VTE all cause healthcare costs were defined as the costs associated with the first recurrent VTE hospitalization and all subsequent VTE costs in the inpatient (primary or secondary diagnosis) or outpatient (any position) setting. Costs were converted to 2021 USD using the medical component of the consumer price index and was expressed as cost per participant per month. The date of the first apixaban or LMWH prescription on or within the 30 days following a VTE diagnosis was considered as the index date. |
| Mean All-Cause Healthcare Outpatient Medical Costs PPPM for Recurrent VTE Events | From index date until health plan disenrollment, index therapy discontinuation, switch to another anticoagulant or end of study period (up to 72 months); data observed retrospectively over 24 months | Recurrent VTE was identified based on inpatient claims with VTE as the primary diagnosis on any claim (ICD-10-CM diagnosis codes). Recurrent VTE outpatient medical costs included costs associated with physician office visits, emergency room visits, laboratory or pathology visits, radiology exams, and outpatient surgical visits. Costs were converted to 2021 USD using the medical component of the consumer price index and was expressed as cost per participant per month. The date of the first apixaban or LMWH prescription on or within the 30 days following a VTE diagnosis was considered as the index date. |
| Mean All-Cause Healthcare Hospitalization Costs PPPM for Recurrent VTE Events | From index date until health plan disenrollment, index therapy discontinuation, switch to another anticoagulant or end of study period (up to 72 months); data observed retrospectively over 24 months | Recurrent VTE was identified based on inpatient claims with VTE as the primary diagnosis on any claim (ICD-10-CM diagnosis codes). The all-cause healthcare hospitalization cost for recurrent VTE event was defined as the cost associated with the inpatient hospitalization for the recurrent VTE event. Costs were converted to 2021 USD using the medical component of the consumer price index and was expressed as cost per participant per month. The date of the first apixaban or LMWH prescription on or within the 30 days following a VTE diagnosis was considered as the index date. |
| Mean All-Cause Healthcare Costs PPPM for Major Bleeding Related VTE Events | From index date until health plan disenrollment, index therapy discontinuation, switch to another anticoagulant or end of study period (up to 72 months); data observed retrospectively over 24 months | Major bleeding was defined by primary discharge diagnosis on any claim in the inpatient setting, including gastrointestinal (GI) bleeding, intracranial hemorrhage (ICH), and other major bleeding. Major bleeding-related all cause healthcare costs were defined as costs associated with the first major bleeding hospitalization plus all subsequent bleeding costs occurring in the inpatient (primary or secondary diagnosis) or outpatient setting (any position). Costs were converted to 2021 USD using the medical component of the consumer price index and was expressed as cost per participant per month. The date of the first apixaban or LMWH prescription on or within the 30 days following a VTE diagnosis was considered as the index date. |
| Mean All-Cause Outpatient Medical Costs PPPM for Major Bleeding Related VTE Events | From index date until health plan disenrollment, index therapy discontinuation, switch to another anticoagulant or end of study period (up to 72 months); data observed retrospectively over 24 months | Major bleeding was defined by primary discharge diagnosis on any claim in the inpatient setting, including GI bleeding, ICH and other major bleeding. Major bleeding-related all cause outpatient medical costs were major bleeding related outpatient costs associated with physician office visits, emergency room visits, laboratory or pathology visits, radiology exams, and outpatient surgical visits. Costs were converted to 2021 USD using the medical component of the consumer price index and was expressed as cost per participant per month. The date of the first apixaban or LMWH prescription on or within the 30 days following a VTE diagnosis was considered as the index date. |
| Mean All-Cause Hospitalization Costs PPPM for Major Bleeding Related VTE Events | From index date until health plan disenrollment, index therapy discontinuation, switch to another anticoagulant or end of study period (up to 72 months); data observed retrospectively over 24 months | Major bleeding was defined by primary discharge diagnosis on any claim in the inpatient setting, including GI bleeding, ICH, and other major bleeding. Major bleeding-related all cause healthcare costs were defined as costs associated with the first major bleeding hospitalization plus all subsequent bleeding costs occurring in the inpatient (primary or secondary diagnosis). Costs were converted to 2021 USD using the medical component of the consumer price index and was expressed as cost per participant per month. The date of the first apixaban or LMWH prescription on or within the 30 days following a VTE diagnosis was considered as the index date. |
| Mean All-Cause Healthcare Costs PPPM for Clinically Relevant Non-Major (CRNM) Bleeding Related VTE Events | From index date until health plan disenrollment, index therapy discontinuation, switch to another anticoagulant or end of study period (up to 72 months); data observed retrospectively over 24 months | CRNM bleeding-related all cause healthcare costs were combination of bleeding related inpatient and outpatient costs. CRNM bleeding was defined as an inpatient encounter with a secondary diagnosis code for bleeding (without a major bleeding code in the primary position) or an outpatient encounter with a diagnosis code in any position for CRNM GI bleeding or other non-critical types of bleeding. Any CRNM bleeding events that followed a major bleeding event were not included in the analysis of CRNM bleeding. Costs were converted to 2021 USD using the medical component of the consumer price index and was expressed as cost per participant per month. The date of the first apixaban or LMWH prescription on or within the 30 days following a VTE diagnosis was considered as the index date. |
| Mean All-Cause Outpatient Medical Costs PPPM for CRNM Bleeding Related VTE Events | From index date until health plan disenrollment, index therapy discontinuation, switch to another anticoagulant or end of study period (up to 72 months); data observed retrospectively over 24 months | CRNM bleeding was defined as an inpatient encounter with a secondary diagnosis code for bleeding (without a major bleeding code in the primary position) or an outpatient encounter with a diagnosis code in any position for CRNM GI bleeding or other non-critical types of bleeding. CRNM bleeding all cause outpatient medical costs were major bleeding related outpatient costs associated with physician office visits, emergency room (ER) visits, laboratory or pathology visits, radiology exams, and outpatient surgical visits. Any CRNM bleeding events that followed a major bleeding event were not included in the analysis of CRNM bleeding. Costs were converted to 2021 USD using the medical component of the consumer price index and was expressed as cost per participant per month. The date of the first apixaban or LMWH prescription on or within the 30 days following a VTE diagnosis was considered as the index date. |
| Mean All-Cause Healthcare Costs Per Participant Per Month (PPPM) for VTE Events | From index date until health plan disenrollment, index therapy discontinuation, switch to another anticoagulant or end of study period (up to 72 months); data observed retrospectively over 24 months | The all-cause healthcare cost for VTE event was defined as the sum of total cost associated with the total inpatient, total outpatient, and total pharmacy costs for the VTE event. Costs were converted to 2021 United States dollars (USD) using the medical component of the consumer price index and was expressed as cost per participant per month. The date of the first apixaban or LMWH prescription on or within the 30 days following a VTE diagnosis was considered as the index date. |
| Mean All-Cause Healthcare Outpatient Pharmacy Costs PPPM for VTE Events | From index date until health plan disenrollment, index therapy discontinuation, switch to another anticoagulant or end of study period (up to 72 months); data observed retrospectively over 24 months | The all-cause healthcare outpatient pharmacy cost for VTE event was defined as the total cost associated with the outpatient pharmacy costs for the VTE event. Costs were converted to 2021 USD using the medical component of the consumer price index and was expressed as cost per participant per month. The date of the first apixaban or LMWH prescription on or within the 30 days following a VTE diagnosis was considered as the index date. |
| Mean All-Cause Healthcare Outpatient Medical Costs PPPM for VTE Events | From index date until health plan disenrollment, index therapy discontinuation, switch to another anticoagulant or end of study period (up to 72 months); data observed retrospectively over 24 months | The all-cause healthcare outpatient medical cost for VTE event was defined as the total cost associated with the outpatient medical costs (excluding pharmacy costs) for the VTE event. Costs were converted to 2021 USD using the medical component of the consumer price index and was expressed as cost per participant per month. The date of the first apixaban or LMWH prescription on or within the 30 days following a VTE diagnosis was considered as the index date. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Mean Number of Outpatient Medical Visits PPPM for VTE Events | From index date until health plan disenrollment, index therapy discontinuation, switch to another anticoagulant or end of study period (up to 72 months); data observed retrospectively over 24 months | Mean number of outpatient medical visits PPPM for VTE events are reported in this outcome measure. Outpatient visits included physician office visits, ER visits, laboratory or pathology visits, radiology exams, and outpatient surgical visits and ancillary or other services. Index date was defined as the date of the first apixaban or LMWH prescription claim on or within the 30 days following a VTE diagnosis. |
| Mean Number of Prescription Fills PPPM for VTE Events | From index date until health plan disenrollment, index therapy discontinuation, switch to another anticoagulant or end of study period (up to 72 months); data observed retrospectively over 24 months | Mean number of prescription fills PPPM for VTE events are reported in this outcome measure. Index date was defined as the date of the first apixaban or LMWH prescription claim on or within the 30 days following a VTE diagnosis. |
| Mean Number of Hospitalizations PPPM for Recurrent VTE Events | From index date until health plan disenrollment, index therapy discontinuation, switch to another anticoagulant or end of study period (up to 72 months); data observed retrospectively over 24 months | Recurrent VTE was identified based on inpatient claims with VTE as the primary diagnosis on any claim (ICD-10-CM diagnosis codes). Mean number of hospitalizations PPPM for recurrent VTE events are reported in this outcome measure. Index date was defined as the date of the first apixaban or LMWH prescription claim on or within the 30 days following a VTE diagnosis. |
| Mean Number of Outpatient Medical Visits PPPM for Recurrent VTE Events | From index date until health plan disenrollment, index therapy discontinuation, switch to another anticoagulant or end of study period (up to 72 months); data observed retrospectively over 24 months | Recurrent VTE was identified based on inpatient claims with VTE as the primary diagnosis on any claim (ICD-10-CM diagnosis codes). Outpatient visits included physician office visits, ER only visits, laboratory or pathology visits, radiology, and surgical services and ancillary or other services. Index date was defined as the date of the first apixaban or LMWH prescription claim on or within the 30 days following a VTE diagnosis. |
| Mean Number of Hospitalizations PPPM for Major Bleeding Related VTE Events | From index date until health plan disenrollment, index therapy discontinuation, switch to another anticoagulant or end of study period (up to 72 months); data observed retrospectively over 24 months | Major bleeding was defined by primary discharge diagnosis on any claim in the inpatient setting, including GI bleeding, ICH and other major bleeding. Mean number of hospitalizations PPPM for recurrent VTE events are reported in this outcome measure. Index date was defined as the date of the first apixaban or LMWH prescription claim on or within the 30 days following a VTE diagnosis. |
| Mean Number of Outpatient Medical Visits PPPM for Major Bleeding Related VTE Events | From index date until health plan disenrollment, index therapy discontinuation, switch to another anticoagulant or end of study period (up to 72 months); data observed retrospectively over 24 months | Major bleeding was defined by primary discharge diagnosis on any claim in the inpatient setting, including GI bleeding, ICH and other major bleeding. Outpatient visits included physician office visits, ER only visits, laboratory or pathology visits, radiology, and surgical services and ancillary or other services. Index date was defined as the date of the first apixaban or LMWH prescription claim on or within the 30 days following a VTE diagnosis. |
| Mean Number of Hospitalizations PPPM for CRNM Bleeding Related VTE Events | From index date until health plan disenrollment, index therapy discontinuation, switch to another anticoagulant or end of study period (up to 72 months); data observed retrospectively over 24 months | CRNM bleeding was defined as an inpatient encounter with a secondary diagnosis code for bleeding (without a major bleeding code in the primary position) or an outpatient encounter with a diagnosis code in any position for CRNM GI bleeding or other non-critical types of bleeding. Mean number of hospitalizations PPPM for recurrent VTE events are reported in this outcome measure. Index date was defined as the date of the first apixaban or LMWH prescription claim on or within the 30 days following a VTE diagnosis. |
| Mean Number of Outpatient Medical Visits PPPM for CRNM Bleeding Related VTE Events | From index date until health plan disenrollment, index therapy discontinuation, switch to another anticoagulant or end of study period (up to 72 months); data observed retrospectively over 24 months | CRNM bleeding was defined as an inpatient encounter with a secondary diagnosis code for bleeding (without a major bleeding code in the primary position) or an outpatient encounter with a diagnosis code in any position for CRNM GI bleeding or other non-critical types of bleeding. Outpatient visits included physician office visits, ER only visits, laboratory or pathology visits, radiology, and surgical services and ancillary or other services. Index date was defined as the date of the first apixaban or LMWH prescription claim on or within the 30 days following a VTE diagnosis. |
| Mean Number of Hospitalizations Per Participant Per Month (PPPM) for VTE Events | From index date until health plan disenrollment, index therapy discontinuation, switch to another anticoagulant or end of study period (up to 72 months); data observed retrospectively over 24 months | Mean number of hospitalizations PPPM for VTE events are reported in this outcome measure. Index date was defined as the date of the first apixaban or LMWH prescription claim on or within the 30 days following a VTE diagnosis. |
Countries
United States
Participant flow
Recruitment details
Participants with newly diagnosed venous thromboembolism (VTE) with active cancer who initiated apixaban or low molecular weight heparin (LMWH) within 30 days following VTE diagnosis were included in this study and data for eligible participants was retrospectively analyzed using IQVIA's database PharMetrics Plus.
Pre-assignment details
The date of the first apixaban or LMWH prescription was considered as the index date. The analysis was conducted using retrospective data from 01 January 2016 through 31 December 2021. Available data was extracted and evaluated during 24 months of this retrospective observational study.
Participants by arm
| Arm | Count |
|---|---|
| Apixaban Participants with newly diagnosed VTE with active cancer who received apixaban within 30 days following the VTE diagnosis and no other anticoagulant (LMWH, other OAC, heparin or fondaparinux) between index VTE encounter date (first date of claim with a VTE diagnosis code) and the index date. | 4,299 |
| LMWH Participants with newly diagnosed VTE with active cancer who received LMWH within 30 days following the VTE diagnosis with a duration of at least 14 days and no apixaban or other anticoagulants between index VTE encounter and index date + 14 days. | 3,005 |
| Total | 7,304 |
Baseline characteristics
| Characteristic | LMWH | Total | Apixaban |
|---|---|---|---|
| Age, Customized 18-24 years | 54 Participants | 83 Participants | 29 Participants |
| Age, Customized 25-34 years | 79 Participants | 154 Participants | 75 Participants |
| Age, Customized 35-44 years | 239 Participants | 473 Participants | 234 Participants |
| Age, Customized 45-54 years | 621 Participants | 1423 Participants | 802 Participants |
| Age, Customized 55-64 years | 1406 Participants | 3357 Participants | 1951 Participants |
| Age, Customized 65-74 years | 458 Participants | 1257 Participants | 799 Participants |
| Age, Customized >= 75 years | 148 Participants | 557 Participants | 409 Participants |
| Race and Ethnicity Not Collected | — | 0 Participants | — |
| Sex: Female, Male Female | 1558 Participants | 3677 Participants | 2119 Participants |
| Sex: Female, Male Male | 1447 Participants | 3627 Participants | 2180 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 0 | 0 / 0 |
| other Total, other adverse events | 0 / 0 | 0 / 0 |
| serious Total, serious adverse events | 0 / 0 | 0 / 0 |
Outcome results
Primary
Mean All-Cause Healthcare Costs Per Participant Per Month (PPPM) for VTE Events
The all-cause healthcare cost for VTE event was defined as the sum of total cost associated with the total inpatient, total outpatient, and total pharmacy costs for the VTE event. Costs were converted to 2021 United States dollars (USD) using the medical component of the consumer price index and was expressed as cost per participant per month. The date of the first apixaban or LMWH prescription on or within the 30 days following a VTE diagnosis was considered as the index date.
Time frame: From index date until health plan disenrollment, index therapy discontinuation, switch to another anticoagulant or end of study period (up to 72 months); data observed retrospectively over 24 months
Population: Analysis population included all participants whose data were included and observed in the study. Here, Overall Number of Participants Analyzed reflects the pseudo-population created using stabilized inverse probability of treatment weighting (IPTW). Hence, numbers are different here from those presented in participant flow and baseline section.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Apixaban | Mean All-Cause Healthcare Costs Per Participant Per Month (PPPM) for VTE Events | 16420 USD per participant per month | Standard Deviation 23354 |
| LMWH | Mean All-Cause Healthcare Costs Per Participant Per Month (PPPM) for VTE Events | 21312 USD per participant per month | Standard Deviation 27337 |
p-value: <0.0001Weighted t-test
Primary
Mean All-Cause Healthcare Costs PPPM for Clinically Relevant Non-Major (CRNM) Bleeding Related VTE Events
CRNM bleeding-related all cause healthcare costs were combination of bleeding related inpatient and outpatient costs. CRNM bleeding was defined as an inpatient encounter with a secondary diagnosis code for bleeding (without a major bleeding code in the primary position) or an outpatient encounter with a diagnosis code in any position for CRNM GI bleeding or other non-critical types of bleeding. Any CRNM bleeding events that followed a major bleeding event were not included in the analysis of CRNM bleeding. Costs were converted to 2021 USD using the medical component of the consumer price index and was expressed as cost per participant per month. The date of the first apixaban or LMWH prescription on or within the 30 days following a VTE diagnosis was considered as the index date.
Time frame: From index date until health plan disenrollment, index therapy discontinuation, switch to another anticoagulant or end of study period (up to 72 months); data observed retrospectively over 24 months
Population: Analysis population included all participants whose data were included and observed in the study. Here, Overall Number of Participants Analyzed reflects the pseudo-population created using stabilized IPTW and who were evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Apixaban | Mean All-Cause Healthcare Costs PPPM for Clinically Relevant Non-Major (CRNM) Bleeding Related VTE Events | 4883 USD per participant per month | Standard Deviation 13142 |
| LMWH | Mean All-Cause Healthcare Costs PPPM for Clinically Relevant Non-Major (CRNM) Bleeding Related VTE Events | 5227 USD per participant per month | Standard Deviation 14230 |
p-value: =0.6066Weighted t-test
Primary
Mean All-Cause Healthcare Costs PPPM for Major Bleeding Related VTE Events
Major bleeding was defined by primary discharge diagnosis on any claim in the inpatient setting, including gastrointestinal (GI) bleeding, intracranial hemorrhage (ICH), and other major bleeding. Major bleeding-related all cause healthcare costs were defined as costs associated with the first major bleeding hospitalization plus all subsequent bleeding costs occurring in the inpatient (primary or secondary diagnosis) or outpatient setting (any position). Costs were converted to 2021 USD using the medical component of the consumer price index and was expressed as cost per participant per month. The date of the first apixaban or LMWH prescription on or within the 30 days following a VTE diagnosis was considered as the index date.
Time frame: From index date until health plan disenrollment, index therapy discontinuation, switch to another anticoagulant or end of study period (up to 72 months); data observed retrospectively over 24 months
Population: Analysis population included all participants whose data were included and observed in the study. Here, Overall Number of Participants Analyzed reflects the pseudo-population created using stabilized IPTW and who were evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Apixaban | Mean All-Cause Healthcare Costs PPPM for Major Bleeding Related VTE Events | 19384 USD per participant per month | Standard Deviation 30260 |
| LMWH | Mean All-Cause Healthcare Costs PPPM for Major Bleeding Related VTE Events | 22719 USD per participant per month | Standard Deviation 30865 |
p-value: =0.2592Weighted t-test
Primary
Mean All-Cause Healthcare Costs PPPM for Recurrent VTE Events
Recurrent VTE was identified based on inpatient claims with VTE as the primary diagnosis on any claim (international classification of diseases, tenth revision, clinical modification \[ICD-10-CM\] diagnosis codes). Recurrent VTE all cause healthcare costs were defined as the costs associated with the first recurrent VTE hospitalization and all subsequent VTE costs in the inpatient (primary or secondary diagnosis) or outpatient (any position) setting. Costs were converted to 2021 USD using the medical component of the consumer price index and was expressed as cost per participant per month. The date of the first apixaban or LMWH prescription on or within the 30 days following a VTE diagnosis was considered as the index date.
Time frame: From index date until health plan disenrollment, index therapy discontinuation, switch to another anticoagulant or end of study period (up to 72 months); data observed retrospectively over 24 months
Population: Analysis population included all participants whose data were included and observed in the study. Here, Overall Number of Participants Analyzed reflects the pseudo-population created using stabilized IPTW and who were evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Apixaban | Mean All-Cause Healthcare Costs PPPM for Recurrent VTE Events | 11277 USD per participant per month | Standard Deviation 19873 |
| LMWH | Mean All-Cause Healthcare Costs PPPM for Recurrent VTE Events | 13074 USD per participant per month | Standard Deviation 21342 |
p-value: =0.2303Weighted t-test
Primary
Mean All-Cause Healthcare Hospitalization Costs PPPM for Recurrent VTE Events
Recurrent VTE was identified based on inpatient claims with VTE as the primary diagnosis on any claim (ICD-10-CM diagnosis codes). The all-cause healthcare hospitalization cost for recurrent VTE event was defined as the cost associated with the inpatient hospitalization for the recurrent VTE event. Costs were converted to 2021 USD using the medical component of the consumer price index and was expressed as cost per participant per month. The date of the first apixaban or LMWH prescription on or within the 30 days following a VTE diagnosis was considered as the index date.
Time frame: From index date until health plan disenrollment, index therapy discontinuation, switch to another anticoagulant or end of study period (up to 72 months); data observed retrospectively over 24 months
Population: Analysis population included all participants whose data were included and observed in the study. Here, Overall Number of Participants Analyzed reflects the pseudo-population created using stabilized IPTW and who were evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Apixaban | Mean All-Cause Healthcare Hospitalization Costs PPPM for Recurrent VTE Events | 10450 USD per participant per month | Standard Deviation 19670 |
| LMWH | Mean All-Cause Healthcare Hospitalization Costs PPPM for Recurrent VTE Events | 12190 USD per participant per month | Standard Deviation 21175 |
p-value: =0.2414Weighted t-test
Primary
Mean All-Cause Healthcare Hospitalization Costs PPPM for VTE Events
The all-cause healthcare hospitalization cost for VTE event was defined as the cost associated with the inpatient hospitalization for the VTE event. Costs were converted to 2021 USD using the medical component of the consumer price index and was expressed as cost per participant per month. The date of the first apixaban or LMWH prescription on or within the 30 days following a VTE diagnosis was considered as the index date.
Time frame: From index date until health plan disenrollment, index therapy discontinuation, switch to another anticoagulant or end of study period (up to 72 months); data observed retrospectively over 24 months
Population: Analysis population included all participants whose data were included and observed in the study. Here, Overall Number of Participants Analyzed reflects the pseudo-population created using stabilized IPTW. Hence, numbers are different here from those presented in participant flow and baseline section.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Apixaban | Mean All-Cause Healthcare Hospitalization Costs PPPM for VTE Events | 5940 USD per participant per month | Standard Deviation 17512 |
| LMWH | Mean All-Cause Healthcare Hospitalization Costs PPPM for VTE Events | 8616 USD per participant per month | Standard Deviation 22667 |
p-value: <0.0001Weighted t-test
Primary
Mean All-Cause Healthcare Outpatient Medical Costs PPPM for Recurrent VTE Events
Recurrent VTE was identified based on inpatient claims with VTE as the primary diagnosis on any claim (ICD-10-CM diagnosis codes). Recurrent VTE outpatient medical costs included costs associated with physician office visits, emergency room visits, laboratory or pathology visits, radiology exams, and outpatient surgical visits. Costs were converted to 2021 USD using the medical component of the consumer price index and was expressed as cost per participant per month. The date of the first apixaban or LMWH prescription on or within the 30 days following a VTE diagnosis was considered as the index date.
Time frame: From index date until health plan disenrollment, index therapy discontinuation, switch to another anticoagulant or end of study period (up to 72 months); data observed retrospectively over 24 months
Population: Analysis population included all participants whose data were included and observed in the study. Here, Overall Number of Participants Analyzed reflects the pseudo-population created using stabilized IPTW and who were evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Apixaban | Mean All-Cause Healthcare Outpatient Medical Costs PPPM for Recurrent VTE Events | 827 USD per participant per month | Standard Deviation 2367 |
| LMWH | Mean All-Cause Healthcare Outpatient Medical Costs PPPM for Recurrent VTE Events | 884 USD per participant per month | Standard Deviation 2430 |
p-value: =0.7403Weighted t-test
Primary
Mean All-Cause Healthcare Outpatient Medical Costs PPPM for VTE Events
The all-cause healthcare outpatient medical cost for VTE event was defined as the total cost associated with the outpatient medical costs (excluding pharmacy costs) for the VTE event. Costs were converted to 2021 USD using the medical component of the consumer price index and was expressed as cost per participant per month. The date of the first apixaban or LMWH prescription on or within the 30 days following a VTE diagnosis was considered as the index date.
Time frame: From index date until health plan disenrollment, index therapy discontinuation, switch to another anticoagulant or end of study period (up to 72 months); data observed retrospectively over 24 months
Population: Analysis population included all participants whose data were included and observed in the study. Here, Overall Number of Participants Analyzed reflects the pseudo-population created using stabilized IPTW. Hence, numbers are different here from those presented in participant flow and baseline section.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Apixaban | Mean All-Cause Healthcare Outpatient Medical Costs PPPM for VTE Events | 8028 USD per participant per month | Standard Deviation 11644 |
| LMWH | Mean All-Cause Healthcare Outpatient Medical Costs PPPM for VTE Events | 10042 USD per participant per month | Standard Deviation 12759 |
p-value: <0.0001Weighted t-test
Primary
Mean All-Cause Healthcare Outpatient Pharmacy Costs PPPM for VTE Events
The all-cause healthcare outpatient pharmacy cost for VTE event was defined as the total cost associated with the outpatient pharmacy costs for the VTE event. Costs were converted to 2021 USD using the medical component of the consumer price index and was expressed as cost per participant per month. The date of the first apixaban or LMWH prescription on or within the 30 days following a VTE diagnosis was considered as the index date.
Time frame: From index date until health plan disenrollment, index therapy discontinuation, switch to another anticoagulant or end of study period (up to 72 months); data observed retrospectively over 24 months
Population: Analysis population included all participants whose data were included and observed in the study. Here, Overall Number of Participants Analyzed reflects the pseudo-population created using stabilized IPTW. Hence, numbers are different here from those presented in participant flow and baseline section.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Apixaban | Mean All-Cause Healthcare Outpatient Pharmacy Costs PPPM for VTE Events | 2452 USD per participant per month | Standard Deviation 5376 |
| LMWH | Mean All-Cause Healthcare Outpatient Pharmacy Costs PPPM for VTE Events | 2654 USD per participant per month | Standard Deviation 4701 |
p-value: <0.0001Weighted t-test
Primary
Mean All-Cause Hospitalization Costs PPPM for CRNM Bleeding Related VTE Events
CRNM bleeding was defined as an inpatient encounter with a secondary diagnosis code for bleeding (without a major bleeding code in the primary position) or an outpatient encounter with a diagnosis code in any position for CRNM GI bleeding or other non-critical types of bleeding. Any CRNM bleeding events that followed a major bleeding event were not included in the analysis of CRNM bleeding. Costs were converted to 2021 USD using the medical component of the consumer price index and was expressed as cost per participant per month. The date of the first apixaban or LMWH prescription on or within the 30 days following a VTE diagnosis was considered as the index date.
Time frame: From index date until health plan disenrollment, index therapy discontinuation, switch to another anticoagulant or end of study period (up to 72 months); data observed retrospectively over 24 months
Population: Analysis population included all participants whose data were included and observed in the study. Here, Overall Number of Participants Analyzed reflects the pseudo-population created using stabilized IPTW and who were evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Apixaban | Mean All-Cause Hospitalization Costs PPPM for CRNM Bleeding Related VTE Events | 4452 USD per participant per month | Standard Deviation 13126 |
| LMWH | Mean All-Cause Hospitalization Costs PPPM for CRNM Bleeding Related VTE Events | 4744 USD per participant per month | Standard Deviation 14232 |
p-value: =0.6618Weighted t-test
Primary
Mean All-Cause Hospitalization Costs PPPM for Major Bleeding Related VTE Events
Major bleeding was defined by primary discharge diagnosis on any claim in the inpatient setting, including GI bleeding, ICH, and other major bleeding. Major bleeding-related all cause healthcare costs were defined as costs associated with the first major bleeding hospitalization plus all subsequent bleeding costs occurring in the inpatient (primary or secondary diagnosis). Costs were converted to 2021 USD using the medical component of the consumer price index and was expressed as cost per participant per month. The date of the first apixaban or LMWH prescription on or within the 30 days following a VTE diagnosis was considered as the index date.
Time frame: From index date until health plan disenrollment, index therapy discontinuation, switch to another anticoagulant or end of study period (up to 72 months); data observed retrospectively over 24 months
Population: Analysis population included all participants whose data were included and observed in the study. Here, Overall Number of Participants Analyzed reflects the pseudo-population created using stabilized IPTW and who were evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Apixaban | Mean All-Cause Hospitalization Costs PPPM for Major Bleeding Related VTE Events | 19116 USD per participant per month | Standard Deviation 30241 |
| LMWH | Mean All-Cause Hospitalization Costs PPPM for Major Bleeding Related VTE Events | 22373 USD per participant per month | Standard Deviation 30822 |
p-value: =0.1355Weighted t-test
Primary
Mean All-Cause Outpatient Medical Costs PPPM for CRNM Bleeding Related VTE Events
CRNM bleeding was defined as an inpatient encounter with a secondary diagnosis code for bleeding (without a major bleeding code in the primary position) or an outpatient encounter with a diagnosis code in any position for CRNM GI bleeding or other non-critical types of bleeding. CRNM bleeding all cause outpatient medical costs were major bleeding related outpatient costs associated with physician office visits, emergency room (ER) visits, laboratory or pathology visits, radiology exams, and outpatient surgical visits. Any CRNM bleeding events that followed a major bleeding event were not included in the analysis of CRNM bleeding. Costs were converted to 2021 USD using the medical component of the consumer price index and was expressed as cost per participant per month. The date of the first apixaban or LMWH prescription on or within the 30 days following a VTE diagnosis was considered as the index date.
Time frame: From index date until health plan disenrollment, index therapy discontinuation, switch to another anticoagulant or end of study period (up to 72 months); data observed retrospectively over 24 months
Population: Analysis population included all participants whose data were included and observed in the study. Here, Overall Number of Participants Analyzed reflects the pseudo-population created using stabilized IPTW and who were evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Apixaban | Mean All-Cause Outpatient Medical Costs PPPM for CRNM Bleeding Related VTE Events | 431 USD per participant per month | Standard Deviation 1134 |
| LMWH | Mean All-Cause Outpatient Medical Costs PPPM for CRNM Bleeding Related VTE Events | 483 USD per participant per month | Standard Deviation 1291 |
p-value: =0.3795Weighted t-test
Primary
Mean All-Cause Outpatient Medical Costs PPPM for Major Bleeding Related VTE Events
Major bleeding was defined by primary discharge diagnosis on any claim in the inpatient setting, including GI bleeding, ICH and other major bleeding. Major bleeding-related all cause outpatient medical costs were major bleeding related outpatient costs associated with physician office visits, emergency room visits, laboratory or pathology visits, radiology exams, and outpatient surgical visits. Costs were converted to 2021 USD using the medical component of the consumer price index and was expressed as cost per participant per month. The date of the first apixaban or LMWH prescription on or within the 30 days following a VTE diagnosis was considered as the index date.
Time frame: From index date until health plan disenrollment, index therapy discontinuation, switch to another anticoagulant or end of study period (up to 72 months); data observed retrospectively over 24 months
Population: Analysis population included all participants whose data were included and observed in the study. Here, Overall Number of Participants Analyzed reflects the pseudo-population created using stabilized IPTW and who were evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Apixaban | Mean All-Cause Outpatient Medical Costs PPPM for Major Bleeding Related VTE Events | 268 USD per participant per month | Standard Deviation 1021 |
| LMWH | Mean All-Cause Outpatient Medical Costs PPPM for Major Bleeding Related VTE Events | 346 USD per participant per month | Standard Deviation 1256 |
p-value: =0.4837Weighted t-test
Secondary
Mean Number of Hospitalizations Per Participant Per Month (PPPM) for VTE Events
Mean number of hospitalizations PPPM for VTE events are reported in this outcome measure. Index date was defined as the date of the first apixaban or LMWH prescription claim on or within the 30 days following a VTE diagnosis.
Time frame: From index date until health plan disenrollment, index therapy discontinuation, switch to another anticoagulant or end of study period (up to 72 months); data observed retrospectively over 24 months
Population: Analysis population included all participants whose data were included and observed in the study. Here, Overall Number of Participants Analyzed reflects the pseudo-population created using stabilized IPTW and who were evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Apixaban | Mean Number of Hospitalizations Per Participant Per Month (PPPM) for VTE Events | 0.4 Hospitalizations PPPM | Standard Deviation 0.4 |
| LMWH | Mean Number of Hospitalizations Per Participant Per Month (PPPM) for VTE Events | 0.4 Hospitalizations PPPM | Standard Deviation 0.4 |
p-value: =0.2337Weighted t-test
Secondary
Mean Number of Hospitalizations PPPM for CRNM Bleeding Related VTE Events
CRNM bleeding was defined as an inpatient encounter with a secondary diagnosis code for bleeding (without a major bleeding code in the primary position) or an outpatient encounter with a diagnosis code in any position for CRNM GI bleeding or other non-critical types of bleeding. Mean number of hospitalizations PPPM for recurrent VTE events are reported in this outcome measure. Index date was defined as the date of the first apixaban or LMWH prescription claim on or within the 30 days following a VTE diagnosis.
Time frame: From index date until health plan disenrollment, index therapy discontinuation, switch to another anticoagulant or end of study period (up to 72 months); data observed retrospectively over 24 months
Population: Analysis population included all participants whose data were included and observed in the study. Here, Overall Number of Participants Analyzed reflects the pseudo-population created using stabilized IPTW and who were evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Apixaban | Mean Number of Hospitalizations PPPM for CRNM Bleeding Related VTE Events | 0.5 Hospitalizations PPPM | Standard Deviation 0.4 |
| LMWH | Mean Number of Hospitalizations PPPM for CRNM Bleeding Related VTE Events | 0.5 Hospitalizations PPPM | Standard Deviation 0.4 |
p-value: =0.566Weighted t-test
Secondary
Mean Number of Hospitalizations PPPM for Major Bleeding Related VTE Events
Major bleeding was defined by primary discharge diagnosis on any claim in the inpatient setting, including GI bleeding, ICH and other major bleeding. Mean number of hospitalizations PPPM for recurrent VTE events are reported in this outcome measure. Index date was defined as the date of the first apixaban or LMWH prescription claim on or within the 30 days following a VTE diagnosis.
Time frame: From index date until health plan disenrollment, index therapy discontinuation, switch to another anticoagulant or end of study period (up to 72 months); data observed retrospectively over 24 months
Population: Analysis population included all participants whose data were included and observed in the study. Here, Overall Number of Participants Analyzed reflects the pseudo-population created using stabilized IPTW and who were evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Apixaban | Mean Number of Hospitalizations PPPM for Major Bleeding Related VTE Events | 0.6 Hospitalizations PPPM | Standard Deviation 0.5 |
| LMWH | Mean Number of Hospitalizations PPPM for Major Bleeding Related VTE Events | 0.6 Hospitalizations PPPM | Standard Deviation 0.5 |
p-value: =0.9796Weighted t-test
Secondary
Mean Number of Hospitalizations PPPM for Recurrent VTE Events
Recurrent VTE was identified based on inpatient claims with VTE as the primary diagnosis on any claim (ICD-10-CM diagnosis codes). Mean number of hospitalizations PPPM for recurrent VTE events are reported in this outcome measure. Index date was defined as the date of the first apixaban or LMWH prescription claim on or within the 30 days following a VTE diagnosis.
Time frame: From index date until health plan disenrollment, index therapy discontinuation, switch to another anticoagulant or end of study period (up to 72 months); data observed retrospectively over 24 months
Population: Analysis population included all participants whose data were included and observed in the study. Here, Overall Number of Participants Analyzed reflects the pseudo-population created using stabilized IPTW and who were evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Apixaban | Mean Number of Hospitalizations PPPM for Recurrent VTE Events | 0.6 Hospitalizations PPPM | Standard Deviation 0.5 |
| LMWH | Mean Number of Hospitalizations PPPM for Recurrent VTE Events | 0.6 Hospitalizations PPPM | Standard Deviation 0.5 |
p-value: =0.729Weighted t-test
Secondary
Mean Number of Outpatient Medical Visits PPPM for CRNM Bleeding Related VTE Events
CRNM bleeding was defined as an inpatient encounter with a secondary diagnosis code for bleeding (without a major bleeding code in the primary position) or an outpatient encounter with a diagnosis code in any position for CRNM GI bleeding or other non-critical types of bleeding. Outpatient visits included physician office visits, ER only visits, laboratory or pathology visits, radiology, and surgical services and ancillary or other services. Index date was defined as the date of the first apixaban or LMWH prescription claim on or within the 30 days following a VTE diagnosis.
Time frame: From index date until health plan disenrollment, index therapy discontinuation, switch to another anticoagulant or end of study period (up to 72 months); data observed retrospectively over 24 months
Population: Analysis population included all participants whose data were included and observed in the study. Here, Overall Number of Participants Analyzed (N) reflects the pseudo-population created using stabilized IPTW. All participants reported under N contributed data to table; however, may not have evaluable data for every row. Number analyzed (n)= number of participants evaluable for specified rows.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Apixaban | Mean Number of Outpatient Medical Visits PPPM for CRNM Bleeding Related VTE Events | Physician office visits | 0.3 Outpatient medical visits PPPM | Standard Deviation 0.7 |
| Apixaban | Mean Number of Outpatient Medical Visits PPPM for CRNM Bleeding Related VTE Events | ER only visits | 0.1 Outpatient medical visits PPPM | Standard Deviation 0.2 |
| Apixaban | Mean Number of Outpatient Medical Visits PPPM for CRNM Bleeding Related VTE Events | Laboratory or pathology visits | 0.7 Outpatient medical visits PPPM | Standard Deviation 1.9 |
| Apixaban | Mean Number of Outpatient Medical Visits PPPM for CRNM Bleeding Related VTE Events | Radiology | 0.1 Outpatient medical visits PPPM | Standard Deviation 0.5 |
| Apixaban | Mean Number of Outpatient Medical Visits PPPM for CRNM Bleeding Related VTE Events | Surgical services | 0.1 Outpatient medical visits PPPM | Standard Deviation 0.2 |
| Apixaban | Mean Number of Outpatient Medical Visits PPPM for CRNM Bleeding Related VTE Events | Ancillary or other services | 0.3 Outpatient medical visits PPPM | Standard Deviation 1 |
| LMWH | Mean Number of Outpatient Medical Visits PPPM for CRNM Bleeding Related VTE Events | Surgical services | 0.1 Outpatient medical visits PPPM | Standard Deviation 0.2 |
| LMWH | Mean Number of Outpatient Medical Visits PPPM for CRNM Bleeding Related VTE Events | Physician office visits | 0.4 Outpatient medical visits PPPM | Standard Deviation 0.8 |
| LMWH | Mean Number of Outpatient Medical Visits PPPM for CRNM Bleeding Related VTE Events | Radiology | 0.1 Outpatient medical visits PPPM | Standard Deviation 0.3 |
| LMWH | Mean Number of Outpatient Medical Visits PPPM for CRNM Bleeding Related VTE Events | ER only visits | 0.1 Outpatient medical visits PPPM | Standard Deviation 0.2 |
| LMWH | Mean Number of Outpatient Medical Visits PPPM for CRNM Bleeding Related VTE Events | Ancillary or other services | 0.4 Outpatient medical visits PPPM | Standard Deviation 1.4 |
| LMWH | Mean Number of Outpatient Medical Visits PPPM for CRNM Bleeding Related VTE Events | Laboratory or pathology visits | 0.9 Outpatient medical visits PPPM | Standard Deviation 2.8 |
Comparison: Physician office visitsp-value: =0.0425Weighted t-test
Comparison: ER only visitsp-value: =0.8634Weighted t-test
Comparison: Laboratory or pathology visitsp-value: =0.0399Weighted t-test
Comparison: Radiologyp-value: =0.0996Weighted t-test
Comparison: Surgical servicesp-value: =0.7655Weighted t-test
Comparison: Ancillary or other servicesp-value: =0.1499Weighted t-test
Secondary
Mean Number of Outpatient Medical Visits PPPM for Major Bleeding Related VTE Events
Major bleeding was defined by primary discharge diagnosis on any claim in the inpatient setting, including GI bleeding, ICH and other major bleeding. Outpatient visits included physician office visits, ER only visits, laboratory or pathology visits, radiology, and surgical services and ancillary or other services. Index date was defined as the date of the first apixaban or LMWH prescription claim on or within the 30 days following a VTE diagnosis.
Time frame: From index date until health plan disenrollment, index therapy discontinuation, switch to another anticoagulant or end of study period (up to 72 months); data observed retrospectively over 24 months
Population: Analysis population included all participants whose data were included and observed in the study. Here, Overall Number of Participants Analyzed (N) reflects the pseudo-population created using stabilized IPTW. All participants reported under N contributed data to table; however, may not have evaluable data for every row. Number analyzed (n)= number of participants evaluable for specified rows.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Apixaban | Mean Number of Outpatient Medical Visits PPPM for Major Bleeding Related VTE Events | Physician office visits | 0.3 Outpatient medical visits PPPM | Standard Deviation 0.9 |
| Apixaban | Mean Number of Outpatient Medical Visits PPPM for Major Bleeding Related VTE Events | ER only visits | 0.0 Outpatient medical visits PPPM | Standard Deviation 0.1 |
| Apixaban | Mean Number of Outpatient Medical Visits PPPM for Major Bleeding Related VTE Events | Laboratory or pathology visits | 0.4 Outpatient medical visits PPPM | Standard Deviation 1.6 |
| Apixaban | Mean Number of Outpatient Medical Visits PPPM for Major Bleeding Related VTE Events | Radiology | 0.1 Outpatient medical visits PPPM | Standard Deviation 0.3 |
| Apixaban | Mean Number of Outpatient Medical Visits PPPM for Major Bleeding Related VTE Events | Surgical services | 0.0 Outpatient medical visits PPPM | Standard Deviation 0.2 |
| Apixaban | Mean Number of Outpatient Medical Visits PPPM for Major Bleeding Related VTE Events | Ancillary or other services | 0.2 Outpatient medical visits PPPM | Standard Deviation 0.9 |
| LMWH | Mean Number of Outpatient Medical Visits PPPM for Major Bleeding Related VTE Events | Surgical services | 0.1 Outpatient medical visits PPPM | Standard Deviation 0.4 |
| LMWH | Mean Number of Outpatient Medical Visits PPPM for Major Bleeding Related VTE Events | Physician office visits | 0.5 Outpatient medical visits PPPM | Standard Deviation 1.4 |
| LMWH | Mean Number of Outpatient Medical Visits PPPM for Major Bleeding Related VTE Events | Radiology | 0.0 Outpatient medical visits PPPM | Standard Deviation 0.2 |
| LMWH | Mean Number of Outpatient Medical Visits PPPM for Major Bleeding Related VTE Events | ER only visits | 0.0 Outpatient medical visits PPPM | Standard Deviation 0.2 |
| LMWH | Mean Number of Outpatient Medical Visits PPPM for Major Bleeding Related VTE Events | Ancillary or other services | 0.3 Outpatient medical visits PPPM | Standard Deviation 1.4 |
| LMWH | Mean Number of Outpatient Medical Visits PPPM for Major Bleeding Related VTE Events | Laboratory or pathology visits | 0.3 Outpatient medical visits PPPM | Standard Deviation 1.2 |
Comparison: Physician office visitsp-value: =0.0379Weighted t-test
Comparison: ER only visitsp-value: =0.9034Weighted t-test
Comparison: Laboratory or pathology visitsp-value: =0.5452Weighted t-test
Comparison: Radiologyp-value: =0.1644Weighted t-test
Comparison: Surgical servicesp-value: =0.065Weighted t-test
Comparison: Ancillary or other servicesp-value: =0.3866Weighted t-test
Secondary
Mean Number of Outpatient Medical Visits PPPM for Recurrent VTE Events
Recurrent VTE was identified based on inpatient claims with VTE as the primary diagnosis on any claim (ICD-10-CM diagnosis codes). Outpatient visits included physician office visits, ER only visits, laboratory or pathology visits, radiology, and surgical services and ancillary or other services. Index date was defined as the date of the first apixaban or LMWH prescription claim on or within the 30 days following a VTE diagnosis.
Time frame: From index date until health plan disenrollment, index therapy discontinuation, switch to another anticoagulant or end of study period (up to 72 months); data observed retrospectively over 24 months
Population: Analysis population included all participants whose data were included and observed in the study. Here, Overall Number of Participants Analyzed (N) reflects the pseudo-population created using stabilized IPTW. All participants reported under N contributed data to table; however, may not have evaluable data for every row. Number analyzed (n)= number of participants evaluable for specified rows.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Apixaban | Mean Number of Outpatient Medical Visits PPPM for Recurrent VTE Events | Physician office visits | 0.7 Outpatient medical visits PPPM | Standard Deviation 1.7 |
| Apixaban | Mean Number of Outpatient Medical Visits PPPM for Recurrent VTE Events | ER only visits | 0.0 Outpatient medical visits PPPM | Standard Deviation 0.1 |
| Apixaban | Mean Number of Outpatient Medical Visits PPPM for Recurrent VTE Events | Laboratory or pathology visits | 0.6 Outpatient medical visits PPPM | Standard Deviation 1.8 |
| Apixaban | Mean Number of Outpatient Medical Visits PPPM for Recurrent VTE Events | Radiology | 0.2 Outpatient medical visits PPPM | Standard Deviation 0.6 |
| Apixaban | Mean Number of Outpatient Medical Visits PPPM for Recurrent VTE Events | Surgical services | 0.0 Outpatient medical visits PPPM | Standard Deviation 0.1 |
| Apixaban | Mean Number of Outpatient Medical Visits PPPM for Recurrent VTE Events | Ancillary or other services | 1.1 Outpatient medical visits PPPM | Standard Deviation 3.5 |
| LMWH | Mean Number of Outpatient Medical Visits PPPM for Recurrent VTE Events | Surgical services | 0.0 Outpatient medical visits PPPM | Standard Deviation 0.1 |
| LMWH | Mean Number of Outpatient Medical Visits PPPM for Recurrent VTE Events | Physician office visits | 0.6 Outpatient medical visits PPPM | Standard Deviation 1.6 |
| LMWH | Mean Number of Outpatient Medical Visits PPPM for Recurrent VTE Events | Radiology | 0.2 Outpatient medical visits PPPM | Standard Deviation 0.8 |
| LMWH | Mean Number of Outpatient Medical Visits PPPM for Recurrent VTE Events | ER only visits | 0.0 Outpatient medical visits PPPM | Standard Deviation 0.1 |
| LMWH | Mean Number of Outpatient Medical Visits PPPM for Recurrent VTE Events | Ancillary or other services | 0.7 Outpatient medical visits PPPM | Standard Deviation 2.5 |
| LMWH | Mean Number of Outpatient Medical Visits PPPM for Recurrent VTE Events | Laboratory or pathology visits | 0.8 Outpatient medical visits PPPM | Standard Deviation 2.9 |
Comparison: Physician office visitsp-value: =0.3686Weighted t-test
Comparison: ER only visitsp-value: =0.2747Weighted t-test
Comparison: Laboratory or pathology visitsp-value: =0.1049Weighted t-test
Comparison: Radiologyp-value: =0.8425Weighted t-test
Comparison: Surgical servicesp-value: =0.9755Weighted t-test
Comparison: Ancillary or other servicesp-value: =0.0582Weighted t-test
Secondary
Mean Number of Outpatient Medical Visits PPPM for VTE Events
Mean number of outpatient medical visits PPPM for VTE events are reported in this outcome measure. Outpatient visits included physician office visits, ER visits, laboratory or pathology visits, radiology exams, and outpatient surgical visits and ancillary or other services. Index date was defined as the date of the first apixaban or LMWH prescription claim on or within the 30 days following a VTE diagnosis.
Time frame: From index date until health plan disenrollment, index therapy discontinuation, switch to another anticoagulant or end of study period (up to 72 months); data observed retrospectively over 24 months
Population: Analysis population included all participants whose data were included and observed in the study. Here, Overall Number of Participants Analyzed (N) reflects the pseudo-population created using stabilized IPTW. Hence, numbers are different here from those presented in participant flow and baseline section. All participants reported under N contributed data to table; however, may not have evaluable data for every row. Number analyzed (n)= number of participants evaluable for specified rows.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Apixaban | Mean Number of Outpatient Medical Visits PPPM for VTE Events | ER only visits | 0.2 Outpatient medical visits PPPM | Standard Deviation 0.3 |
| Apixaban | Mean Number of Outpatient Medical Visits PPPM for VTE Events | Radiology | 1.6 Outpatient medical visits PPPM | Standard Deviation 2.8 |
| Apixaban | Mean Number of Outpatient Medical Visits PPPM for VTE Events | Physician office visits | 3.0 Outpatient medical visits PPPM | Standard Deviation 3 |
| Apixaban | Mean Number of Outpatient Medical Visits PPPM for VTE Events | Surgical services | 0.4 Outpatient medical visits PPPM | Standard Deviation 0.7 |
| Apixaban | Mean Number of Outpatient Medical Visits PPPM for VTE Events | laboratory or pathology visits | 5.6 Outpatient medical visits PPPM | Standard Deviation 7 |
| Apixaban | Mean Number of Outpatient Medical Visits PPPM for VTE Events | Ancillary/other services | 6.5 Outpatient medical visits PPPM | Standard Deviation 7 |
| LMWH | Mean Number of Outpatient Medical Visits PPPM for VTE Events | laboratory or pathology visits | 8.1 Outpatient medical visits PPPM | Standard Deviation 9.5 |
| LMWH | Mean Number of Outpatient Medical Visits PPPM for VTE Events | Physician office visits | 3.5 Outpatient medical visits PPPM | Standard Deviation 3.1 |
| LMWH | Mean Number of Outpatient Medical Visits PPPM for VTE Events | ER only visits | 0.2 Outpatient medical visits PPPM | Standard Deviation 0.4 |
| LMWH | Mean Number of Outpatient Medical Visits PPPM for VTE Events | Ancillary/other services | 7.7 Outpatient medical visits PPPM | Standard Deviation 7.1 |
| LMWH | Mean Number of Outpatient Medical Visits PPPM for VTE Events | Radiology | 2.1 Outpatient medical visits PPPM | Standard Deviation 3.1 |
| LMWH | Mean Number of Outpatient Medical Visits PPPM for VTE Events | Surgical services | 0.6 Outpatient medical visits PPPM | Standard Deviation 0.8 |
Comparison: Physician office visitsp-value: <0.0001Weighted t-test
Comparison: ER only visitsp-value: <0.0001Weighted t-test
Comparison: laboratory or pathology visitsp-value: <0.0001Weighted t-test
Comparison: Radiologyp-value: <0.0001Weighted t-test
Comparison: Surgical servicesp-value: <0.0001Weighted t-test
Comparison: Ancillary/other servicesp-value: <0.0001Weighted t-test
Secondary
Mean Number of Prescription Fills PPPM for VTE Events
Mean number of prescription fills PPPM for VTE events are reported in this outcome measure. Index date was defined as the date of the first apixaban or LMWH prescription claim on or within the 30 days following a VTE diagnosis.
Time frame: From index date until health plan disenrollment, index therapy discontinuation, switch to another anticoagulant or end of study period (up to 72 months); data observed retrospectively over 24 months
Population: Analysis population included all participants whose data were included and observed in the study. Here, Overall Number of Participants Analyzed reflects the pseudo-population created using stabilized IPTW and who were evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Apixaban | Mean Number of Prescription Fills PPPM for VTE Events | 5.0 Prescription fills PPPM | Standard Deviation 4.1 |
| LMWH | Mean Number of Prescription Fills PPPM for VTE Events | 5.6 Prescription fills PPPM | Standard Deviation 4.5 |
p-value: <0.0001Weighted t-test